April 25, 2022 02:28 PM EDTUpdated 02:48 PM
Pharma
Manufacturing

Pfiz­er's blood pres­sure meds re­called due to more can­cer-caus­ing con­t­a­m­i­nants

Josh Sullivan

More ni­trosamines, more prob­lems for Pfiz­er.

The Big Phar­ma is re­call­ing five lots of Ac­cupril, a blood pres­sure drug, af­ter it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­gen gets $250M in Roy­al­ty Phar­ma deal for Phase 3 lu­pus pro­gram

Af­ter pass­ing on M&A of­fers, Abcuro rais­es $200M in bid to be­come com­mer­cial drug­mak­er

Ex­clu­sive: Longevi­ty start­up tar­gets rene­gade pro­teins linked to di­a­betes and obe­si­ty

Spring­Works lands FDA ap­proval for nerve tu­mor treat­ment

Bio­haven lands pri­or­i­ty re­view on sec­ond-chance ap­pli­ca­tion for neu­rode­gen­er­a­tive drug

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times